Seizert Capital Partners LLC Takes Position in Solventum Corporation (NYSE:SOLV)

Key Points

• Seizert Capital Partners LLC acquired 58,550 shares of Solventum Corporation, valued at approximately $4.45 million, during the first quarter.
• Solventum reported a net margin of 4.55% and earnings per share of $1.34, exceeding analysts' expectations of $1.19.
• Analysts have issued mixed ratings on Solventum, with the stock currently holding a consensus rating of "Hold" and a price target of $84.38.

Seizert Capital Partners LLC purchased a new stake in Solventum Corporation (NYSE:SOLV - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 58,550 shares of the company's stock, valued at approximately $4,452,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Rossby Financial LCC acquired a new stake in shares of Solventum during the first quarter valued at about $25,000. Clarity Asset Management Inc. bought a new position in Solventum during the 4th quarter valued at $25,000. Raiffeisen Bank International AG bought a new position in Solventum during the 4th quarter valued at $29,000. Hara Capital LLC bought a new position in Solventum during the 1st quarter valued at $38,000. Finally, Colonial Trust Co SC boosted its stake in Solventum by 240.7% during the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after acquiring an additional 361 shares during the last quarter.

Wall Street Analysts Forecast Growth

SOLV has been the subject of a number of research reports. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target for the company in a research note on Tuesday, July 1st. Piper Sandler upgraded Solventum from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $78.00 to $87.00 in a research note on Monday, May 19th. Finally, KeyCorp initiated coverage on Solventum in a research note on Friday, June 6th. They issued a "sector weight" rating for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Solventum currently has a consensus rating of "Hold" and an average price target of $84.38.

Solventum Stock Performance

SOLV stock traded up $0.37 during midday trading on Friday, reaching $71.73. The company had a trading volume of 780,679 shares, compared to its average volume of 560,246. The company has a quick ratio of 0.85, a current ratio of 1.19 and a debt-to-equity ratio of 2.40. The stock has a 50 day moving average price of $74.15 and a 200 day moving average price of $73.01. Solventum Corporation has a fifty-two week low of $54.26 and a fifty-two week high of $85.92. The firm has a market capitalization of $12.41 billion, a PE ratio of 33.21, a P/E/G ratio of 1.83 and a beta of 0.53.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.15. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. Solventum had a return on equity of 31.01% and a net margin of 4.55%. Solventum's quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.08 earnings per share. Analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.